CAM
CRSP icon

Concorde Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Concorde Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,782
Closed -$535K – 174
2021
Q3 		$535K Buy
4,782
+3,267
+216% +$410K 0.31% 109
2021
Q2 		$245K Sell
1,515
-1,330
-47% -$162K 0.14% 160
2021
Q1 		$346K Sell
2,845
-11,867
-81% -$1.79M 0.2% 127
2020
Q4 		$2.25M Buy
14,712
+4,791
+48% +$566K 1.25% 22
2020
Q3 		$830K Buy
+9,921
New +$880K 0.47% 65

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Concorde Asset Management's CRSP Position: Q4 2021 in Review

Concorde Asset Management sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 4,782 shares — an estimated $535K sold.

Concorde Asset Management first reported a position in CRSP in Q3 2020 and held it in 5 quarters. The position peaked at $2.25M in Q4 2020. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Concorde Asset Management reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Concorde Asset Management sold 4,782 CRISPR Therapeutics shares in Q4 2021, an estimated $535K.
  • Concorde Asset Management first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 5 quarters.
  • Concorde Asset Management's CRISPR Therapeutics position peaked at $2.25M in Q4 2020.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Concorde Asset Management's 13F filing for Q4 2021, filed 2 Feb 2022.